Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Capital Stock (Details)

Capital Stock (Details) - USD ($)								12 Months Ended
Capital Stock (Details) - USD ($)	Nov. 17, 2022	Jul. 26, 2022	Jun. 18, 2022	Sep. 17, 2021	Aug. 11, 2021	Jul. 27, 2021	Jan. 06, 2021	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Shares issued (in shares)				273	116,721		38,278
Warrants issued (in shares)							38,278
Purchase price (in usd per share)							$ 209.00
Net proceeds from the private placement							$ 8,000,000
Warrants, exercise price, per share, subject to adjustments (in usd per share)							$ 209.00
Warrant term							5 years
Purchase price (in usd per share)					$ 92.10
Number of warrants issued to purchase the shares (in shares)					5,836
Exercise price (in usd per share)		$ 8.00			$ 115.124
Expiration term					5 years 6 months
Total net proceeds from offerings					$ 9,800,000			$ 5,377,719	$ 17,745,207
Proceeds from warrant exercise and sale	$ 3,100,000
Placement agent transaction fees, equal to percentage of gross proceeds from sale	8.00%
Common Stock Warrants
Class of Stock [Line Items]
Warrant term							6 months
Class A Warrant
Class of Stock [Line Items]
Warrants exercised (in shares)	654,609
Inducement Warrant
Class of Stock [Line Items]
Exercise price (in usd per share)	$ 5.97
Expiration term	18 months
Period from issuance that warrant becomes exercisable	6 months
Panoptes Pharma Ges .m.b.h.
Class of Stock [Line Items]
Issuance of Panoptes holdback shares (in shares)			10,087
Holdback shares, term			18 months
Private Placement Warrants
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)					58,361
Exercise price (in usd per share)					$ 89.60
Expiration term					5 years
Public Offering
Class of Stock [Line Items]
Public offering price (in usd per share)		8.00
Shares issued, price per preferred share, five thousand Class A warrants and five thousand Class B warrants (in usd per share)		$ 1,000
Net proceeds from sale		$ 5,300,000
Underwriting discount and commissions		400,000
Underwriting expenses		$ 300,000
Public Offering \| Class A Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)		30,095,697
Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)		5,000
Public Offering \| Class B Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)		30,095,697
Number of warrants considered for determination of public offering price of preferred shares issued with warrants (in shares)		5,000
Public Offering \| Class A Warrants, Exercise of Option
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)		3,925,525
Public Offering \| Class B Warrant, Exercise Of Option
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)		3,925,525
Preferred Stock
Class of Stock [Line Items]
Conversion of Series C Preferred Stock into Common Stock (in shares)						4,092
Common Stock
Class of Stock [Line Items]
Conversion of Series C Preferred Stock into Common Stock (in shares)						21,313
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Shares issued (in shares)				39
Common Shares
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)		98,138
Common Shares \| Public Offering
Class of Stock [Line Items]
Shares issued (in shares)		592,392
Number of warrants issued to purchase the shares (in shares)		160,000
Warrant convertible into common stock basis		2.50%
Warrants convertible into common stock (in shares)		1,504,785
Series E Convertible Preferred Stock \| Public Offering
Class of Stock [Line Items]
Number of shares convertible (in shares)		1,280
Common Stock \| Inducement Warrant
Class of Stock [Line Items]
Number of warrants issued to purchase the shares (in shares)	654,609